Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations by a Multivariant Surrogate Virus Neutralization Microarray

David Niklas Springer
ORCID logo ,
Eva Höltl
,
Katja Prüger
,
Elisabeth Puchhammer-Stöckl
,
Judith Helene Aberle
ORCID logo ,
Karin Stiasny
,
Lukas Weseslindtner
* ORCID logo
Version 1 : Received: 14 November 2023 / Approved: 15 November 2023 / Online: 15 November 2023 (17:01:16 CET)

How to cite: Springer, D. N.; Höltl, E.; Prüger, K.; Puchhammer-Stöckl, E.; Aberle, J. H.; Stiasny, K.; Weseslindtner, L. Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations by a Multivariant Surrogate Virus Neutralization Microarray. Preprints 2023, 2023111035. https://doi.org/10.20944/preprints202311.1035.v1 Springer, D. N.; Höltl, E.; Prüger, K.; Puchhammer-Stöckl, E.; Aberle, J. H.; Stiasny, K.; Weseslindtner, L. Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations by a Multivariant Surrogate Virus Neutralization Microarray. Preprints 2023, 2023111035. https://doi.org/10.20944/preprints202311.1035.v1

Abstract

The capability of antibodies to neutralize different SARS-CoV-2 variants varies among individuals depending on the previous exposure to wild-type- or Omicron-specific immunogens by mono- or bivalent vaccinations or infections. Such profiles of neutralizing antibodies (nAbs) usually have to be assessed by laborious live virus-neutralization tests (NTs). We therefore analyzed whether a novel multivariant surrogate virus neutralization test (sVNT) (adapted from a commercial microarray) that quantifies the antibody-mediated inhibition between the receptor angiotensin-converting-enzyme 2 (ACE2) and variant-specific receptor-binding domains (RBDs) can assess the neutralizing activity against SARS-CoV-2 wild-type, Delta Omicron BA.1, BA.2 and BA.5 (sub-) variants after a booster with Omicron-adapted bivalent vaccines in a manner similar to live-virus NTs. Indeed, by using the live-virus NTs as a reference, we found a significant correlation between the variant-specific NT titers and levels of ACE2-RBD binding inhibition (p < 0.0001, r ≤ 0.78 respectively). Furthermore, the sVNTs identified higher inhibition values against BA.5 and BA.1 in individuals vaccinated with Omicron-adapted vaccines than in those with monovalent wild-type vaccines. Our data thus demonstrate the ability of sVNTs to detect variant-specific nAbs following a booster with bivalent vaccines.

Keywords

SARS-CoV-2; Omicron; bivalent vaccination; neutralization;  assay; surrogate

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.